Weight loss and antidiabetic drugs are part of the NAFLD therapy and can eventually lead to a resolution of NASH [40] and are therefore a confounding factor regarding ALT levels. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.